Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...

Shares in drugs giant AstraZeneca (AZN) looked perkier today as it reported a rise in sales and eased investor fears over the ...

A revival in AstraZeneca Plc shares faces a key test this week, with more likely to hinge on the drugmaker’s ability to ...

AstraZeneca on Thursday said it could face a fine of up to $4.5 million in China over suspected unpaid import taxes, raising ...

Goldman Sachs updated its price target on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN) shares to GBP150.67, down from GBP155.58, while reaffirming a Buy rating on the stock. The adjustment follows a ...

AstraZeneca investors will look past another strong set of quarterly results on Thursday to focus on the main issue ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

AstraZeneca PLC (LON:AZN – Get Free Report)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of £114.96 ($142.96 ...

AZN is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. Momentum investors should take note of this Medical stock. AZN has a Momentum Style Score of B, and shares are up 6.5% over the past ...